Learn More about Lumida ETF
Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home Lifestyle Health and Longevity

U.S. Life Expectancy Hits Record High as Overdose Deaths Plunge

by Team Lumida
January 29, 2026
in Health and Longevity
Reading Time: 3 mins read
A A
0
U.S. Life Expectancy Hits Record High as Overdose Deaths Plunge
Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp

Key takeaways

Powered by lumidawealth.com

  • U.S. life expectancy rose to 79 years in 2024, the highest on record, up 0.6 years YoY
  • Drug-overdose deaths fell more than 26%, the largest annual decline ever recorded by the CDC
  • The drop in fatalities—especially from fentanyl—was the main driver of the longevity rebound
  • Despite gains, the U.S. continues to lag other developed nations on overall life expectancy

What Happened?

Federal data show U.S. life expectancy climbed to a record level in 2024 after collapsing during the Covid-19 pandemic. The Centers for Disease Control and Prevention reported a sharp reduction in overall mortality, led by a historic fall in drug-overdose deaths. Fatal overdoses dropped from about 31 to 23 deaths per 100,000 people in one year, with the steepest declines among teenagers and young adults. Synthetic opioids such as fentanyl, which had driven the crisis, accounted for far fewer deaths than in prior years.

Why It Matters?

The reversal marks a meaningful public-health inflection point after years in which overdoses and pandemic-related deaths dragged U.S. longevity backward. Fewer premature deaths among working-age adults improve labor force stability, healthcare cost trends, and long-term economic productivity. The data also suggest targeted interventions—such as wider naloxone access and expanded treatment infrastructure—can generate measurable population-level impact. However, the U.S. still underperforms peer countries, signaling persistent structural health challenges in chronic disease, prevention, and social care.

What’s Next?

Provisional data into 2025 indicate overdose deaths continue to decline, which could support further gains in life expectancy. The durability of this trend will depend on continued funding for prevention, addiction treatment, and community health programs. Investors and policymakers will also watch whether progress extends beyond overdose mortality into cardiovascular disease and chronic illness—areas that have historically capped U.S. longevity improvements.

Source
Previous Post

“Trump Accounts” Offer $1,000 for Kids—But the Fine Print Makes Them Tricky for Families

Next Post

Global Tech’s AI Spending Wave Accelerates—and the Supply Chain Is Straining

Recommended For You

94% of Physicians Have Adopted or Want AI — But Accuracy Concerns Remain the Top Barrier

by Team Lumida
23 hours ago
a man holding a ball in his right hand

A Doximity survey of more than 3,000 physicians finds that AI adoption in clinical practice has surged from 47% to 63% in under a year — but more...

Read more

Up to 10 Million Americans Could Lose Medicaid by 2028 Under New Work Requirements

by Team Lumida
2 days ago
Auto Draft

A new Urban Institute and Robert Wood Johnson Foundation analysis finds that 5 to 10 million people could be disenrolled from Medicaid in 2028 due to work requirements...

Read more

One-Third of Americans Now Use AI for Health Advice — and Many Are Skipping the Doctor

by Team Lumida
3 days ago
One-Third of Americans Now Use AI for Health Advice — and Many Are Skipping the Doctor

A KFF poll of 1,300+ U.S. adults finds roughly 1 in 3 now use AI for health information — as often as social media — with 40%+ uploading...

Read more

The Weight Loss Drug Race: What’s Available Now and What’s Coming Next

by Team Lumida
1 week ago
The Weight Loss Drug Race: What’s Available Now and What’s Coming Next

The obesity drug market is set for a major expansion, with Eli Lilly's once-daily pill targeting April FDA approval, Novo Nordisk launching a high-dose shot, and six additional...

Read more

GLP-1s Aren’t a Shortcut. They’re a Powerful Tool That Still Needs a Real Health Strategy

by Team Lumida
1 week ago
GLP-1s Aren’t a Shortcut. They’re a Powerful Tool That Still Needs a Real Health Strategy

Key Takeaways Powered by lumidawealth.com GLP-1 drugs can be highly effective for weight management, but they work best when combined with diet, physical activity, and clinical follow-up. The bigger...

Read more

Sleep Regularity Is the Underrated Health Lever Most People Miss

by Team Lumida
2 weeks ago
woman sleeping on bed under blankets

Key Takeaways Powered by lumidawealth.com A consistent sleep and wake time may be one of the simplest high-impact health habits. Healthy sleep is not just about hours. Regular timing...

Read more

Generic Ozempic Wave Could Redraw the Global GLP-1 Market

by Team Lumida
2 weeks ago
Generic Ozempic Wave Could Redraw the Global GLP-1 Market

Key Takeaways Powered by lumidawealth.com India is set to become the first major market to see a large-scale rollout of generic semaglutide, with at least a dozen major drugmakers...

Read more

Yoga Is the Longevity Habit Most People Underestimate

by Team Lumida
2 weeks ago
woman in black tank top and black pants bending her body on floor

Key takeaways Powered by lumidawealth.com Improves flexibility, balance, and joint health, reducing injury risk with age. Lowers stress and cortisol, supporting heart and metabolic health. Enhances nervous system regulation,...

Read more

Grip Strength Is a Longevity Biomarker

by Team Lumida
2 weeks ago
a person lifting a barbell in a gym

Key takeaways Powered by lumidawealth.com Lower grip strength is linked to higher mortality risk. It correlates with cardiovascular health, muscle mass, and frailty. Declining grip strength often signals system-wide...

Read more

Most “Longevity Drugs” Don’t Work the Way You Think

by Team Lumida
2 weeks ago
diagram

Key takeaways Powered by lumidawealth.com Most longevity drugs improve markers, not actual lifespan. Human evidence is weak for many popular compounds. Drug benefits are context-dependent — not universal. Lifestyle...

Read more
Next Post
China’s AI Startups Challenge Global Leaders Amid U.S. Trade Curbs

Global Tech’s AI Spending Wave Accelerates—and the Supply Chain Is Straining

Coinbase Q2 2024 Earnings Highlights: Diversification Drives Sixth Consecutive Quarter of Positive Adjusted EBITDA

White House Convenes Banks and Crypto Leaders as Coinbase Pulls Support for Key Market-Structure Bill

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

Trump Tariffs Leave Key Questions on China Supply Chain Rules Unanswered

Trump Leans on Foreign Policy Wins as Domestic Pressures Mount

October 31, 2025
four round silver-colored and gold-colored Bitcoins

Bitcoin Surges with $2Bn Inflows, Ether Eyes $10K

June 10, 2024
Blackrock Q2 2024 Earnings Summary

BlackRock’s Bitcoin ETF Sees Historic $333M Daily Outflow, Signaling Market Shift

January 3, 2025

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Latest
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips AI demand Amazon Apple Artificial Intelligence Banking Bitcoin China Commercial Real Estate CPI Crypto Donald Trump EARNINGS ELON MUSK ETF Ethereum Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Nvidia OpenAI private equity S&P 500 SEC Semiconductor stock market Tech Stocks tesla Trump Wells Fargo Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018